Peipert JD, Kulasekararaj AG, Gaya A, Langemeijer SMC, et al. Patient preferences and quality of life implications of ravulizumab (every 8 weeks) and eculizumab (every 2 weeks) for the treatment of paroxysmal nocturnal hemoglobinuria. PLoS One 2020;15:e0237497.
PMID: 32886668